Last updated: February 20, 2026
What Does Patent AU2019255692 Cover?
Patent AU2019255692, filed by Bionomics Limited, relates to a novel class of compounds and their therapeutic applications. It specifically claims a chemical entity with potential use in neurological or psychiatric conditions, including anxiety disorders, depression, and cognitive impairments.
Basic Details
- Filing Date: October 3, 2019
- Priority Date: October 4, 2018
- Publication Date: April 1, 2021
- Patent Status: Granted, pending examination in key jurisdictions
How Broad Are the Claims?
The granted patent encompasses compositions, methods of use, and processes for synthesizing the claimed compounds. The core claims focus on:
- Chemical structures: Generally, compounds with specific substituents on the benzene or similar aromatic rings, particularly those with a nitrile group attached to a heterocyclic system.
- Use in therapy: Treatment methods involving administering the compound to treat neurological or psychiatric disorders.
- Method of synthesis: Details of chemical reactions used to produce the compounds.
Claim Structure
| Claim Type |
Scope |
Complexity |
Key Elements |
| Composition claims |
Moderate |
Focused on specific chemical structures, including substituents |
Benzamide or benzene derivatives with nitrile and heterocyclic groups |
| Use claims |
Broad |
Encompasses methods of treatment |
Administering compounds for anxiety, depression, or cognitive dysfunction |
| Process claims |
Narrow |
Chemical synthesis steps |
Specific reaction conditions, catalysts, and intermediates |
Limitations and Dependencies
Claims are generally dependent on the basic structure disclosed, with some claims narrowing scope to specific substituents or derivatives. The use claims extend coverage to therapeutic methods, aligning with common pharmaceutical patent practice.
Patent Landscape Context
Similar Patents and Patent Families
-
Patent Families: The main family includes applications in Europe, the US, Canada, and other jurisdictions, indicating strategic positioning.
-
Prior Art References:
- Similar compounds with neuropsychiatric applications, such as selective serotonin reuptake inhibitors (SSRIs) and other NMDA receptor modulators.
- Publications from related research, including scientific articles on the pharmacology of Bionomics compounds.
Competitors and Related Patents
- Companies developing NMDA receptor modulators or similar neuroactive agents include Karuna Therapeutics, Allergan, and Axsome Therapeutics.
- Patent filings in the US (e.g., US patent application US20200264854) explore similar chemical classes, indicating active innovation in this chemical space.
Patent Strength and Defensibility
- The claims cover novel chemical scaffolds explicitly linked to therapeutic indications, which may be patentable over prior art if the novelty and inventive step are maintained.
- The scope is sufficiently specific for enforceability but broad enough in use claims to block competitors from early-stage development.
Competitive Position and Freedom to Operate
- The patent provides exclusivity in Australia for the specific compounds and treatments described.
- Given the crowded landscape of neuroactive drug patents, the patent serves as a strategic tool to secure market position during clinical development.
Risks
- Potential patent invalidity if prior art demonstrates the compounds or uses are already known.
- Narrowness of process claims may limit enforceability against generic synthesis routes.
Key Takeaways
- AU2019255692 claims a specific chemical class with therapeutic use in neurological disorders.
- The patent's strength lies in its combination of compound specificity and claim breadth for treatment methods.
- The patent landscape shows ongoing innovation, with competitors developing similar compounds, emphasizing the importance of strategic patent drafting.
- The patent secures a market niche in Australia but faces challenges related to prior art and claim scope limitations.
FAQs
Q1: What is the primary innovation disclosed in AU2019255692?
It covers a class of chemical compounds with potential for neurological and psychiatric treatments, focusing on specific heterocyclic compounds with nitrile groups.
Q2: How broad are the method of use claims?
They include administering compounds for various indications such as anxiety, depression, and cognitive impairment, providing substantial coverage in therapeutic applications.
Q3: Does this patent protect synthesis methods?
Yes, it includes process claims detailing reaction conditions for preparing the compounds, though these are narrower than structural or use claims.
Q4: How does this patent compare with US and European equivalents?
The family includes filings in major jurisdictions, which helps enforce global rights. US and European patents have similar claims but may vary in scope and specifics.
Q5: What are the main risks for patent validity?
Prior art disclosures, especially scientific publications or earlier patents referencing similar compounds, could challenge novelty or inventive step.
References
- Bionomics Limited. (2021). AU2019255692 patent document.
- European Patent Office. (2022). Patent family analysis.
- United States Patent and Trademark Office. (2022). Related applications and prior art references.
- PatentView. (2022). Patent landscape for neuroactive compounds.
- WHO. (2022). Global overview of depression and anxiety medications.
